At the same time, according to the individual differences of patients (such as the expression levels of CD80, CD86 and PD-L1 on the surface of tumor cells), personalized combination treatment plans are formulated to improve the pertinence and effectiveness of treatment. This evidence concerns the gene CD274 and neoplasm.